| Laurian Duncan, AUDIOLOGIST | |
|
2101 N Waldron St, Hutchinson, KS 67502-1131 | |
| (620) 669-2500 | |
| Not Available |
| Full Name | Laurian Duncan |
|---|---|
| Gender | Female |
| Speciality | Audiologist |
| Location | 2101 N Waldron St, Hutchinson, Kansas |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1649244559 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 231H00000X | Audiologist | 1956 (Kansas) | Primary |
| Provider Name | Choctaw Nation Of Oklahoma |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1659347623 PECOS PAC ID: 1759294838 Enrollment ID: O20031106000326 |
News Archive
Researchers at the Infection Biology Unit, German Primate Center, and the Georg-August-University Göttingen in Germany have found that the B.1.351 and P.1 SARS-CoV-2 variants have the potential to evade therapeutic antibodies or antibodies induced by natural infection or vaccination.
The U.S. Food and Drug Administration today announced labeling changes, including a Boxed Warning, to highlight the risks of life-threatening infections, including progressive multifocal leukoencephalopathy (PML), with the use of Raptiva (efalizumab). The labeling changes are based on the FDA's post-market surveillance.
Boehringer Ingelheim, a global pharmaceutical group of companies, together with its U.S. animal health business Boehringer Ingelheim Vetmedica, Inc., announced today that it has entered into an agreement with Pfizer to acquire certain assets of Wyeth Pharmaceutical's Fort Dodge Animal Health business upon the closing of the global Pfizer-Wyeth merger, which is expected to occur early in the fourth quarter.
KemPharm, Inc. announced today that it has received a Notice of Issuance from the United States Patent and Trademark Office (USPTO) for its patent application entitled "Non-Standard Amino Acid Conjugates of Amphetamine and Processes for Making and Using the Same", U.S. Patent No. 7,776,917 B2. This patent, combined with KemPharm's recently issued U.S. Patent No. 7,772,222, provides broad protection of the Company's Ligand Activated Therapy (LAT) prodrug technology platform and its application to the treatment of Attention Deficit – Hyperactivity Disorder.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Laurian Duncan, AUDIOLOGIST 2101 N Waldron St, Hutchinson, KS 67502-1131 Ph: (620) 669-2500 | Laurian Duncan, AUDIOLOGIST 2101 N Waldron St, Hutchinson, KS 67502-1131 Ph: (620) 669-2500 |
News Archive
Researchers at the Infection Biology Unit, German Primate Center, and the Georg-August-University Göttingen in Germany have found that the B.1.351 and P.1 SARS-CoV-2 variants have the potential to evade therapeutic antibodies or antibodies induced by natural infection or vaccination.
The U.S. Food and Drug Administration today announced labeling changes, including a Boxed Warning, to highlight the risks of life-threatening infections, including progressive multifocal leukoencephalopathy (PML), with the use of Raptiva (efalizumab). The labeling changes are based on the FDA's post-market surveillance.
Boehringer Ingelheim, a global pharmaceutical group of companies, together with its U.S. animal health business Boehringer Ingelheim Vetmedica, Inc., announced today that it has entered into an agreement with Pfizer to acquire certain assets of Wyeth Pharmaceutical's Fort Dodge Animal Health business upon the closing of the global Pfizer-Wyeth merger, which is expected to occur early in the fourth quarter.
KemPharm, Inc. announced today that it has received a Notice of Issuance from the United States Patent and Trademark Office (USPTO) for its patent application entitled "Non-Standard Amino Acid Conjugates of Amphetamine and Processes for Making and Using the Same", U.S. Patent No. 7,776,917 B2. This patent, combined with KemPharm's recently issued U.S. Patent No. 7,772,222, provides broad protection of the Company's Ligand Activated Therapy (LAT) prodrug technology platform and its application to the treatment of Attention Deficit – Hyperactivity Disorder.
› Verified 8 days ago
Carrie Claassen, M.A. Audiologist Medicare: Accepting Medicare Assignments Practice Location: 1712 E 23rd Ave, Hutchinson, KS 67502 Phone: 620-662-4458 Fax: 620-662-0538 | |
Megan A Pinkerton, AUD Audiologist Medicare: Accepting Medicare Assignments Practice Location: 2101 N Waldron St, Hutchinson, KS 67502 Phone: 620-669-2500 Fax: 620-694-2128 | |
Jill Hammer, Audiologist Medicare: Accepting Medicare Assignments Practice Location: 2101 N Waldron St, Hutchinson, KS 67502 Phone: 620-669-2500 Fax: 620-694-2170 | |
James Evenson, AUDIOLOGIST Audiologist Medicare: Accepting Medicare Assignments Practice Location: 2101 N Waldron St, Hutchinson, KS 67502 Phone: 620-669-2500 Fax: 620-694-2170 | |
Mrs. Ashley Jeanne Beck, AUD Audiologist Medicare: Accepting Medicare Assignments Practice Location: 2101 N Waldron St, Hutchinson, KS 67502 Phone: 620-669-2500 Fax: 620-694-2128 |